What's New in Hepatitis C and HCC?

March 21, 2009

Click here to view on mobile device

If you are having problems viewing this e-mail, access the content online at:

Advances in Management of Chronic Hepatitis C and Hepatocellular Carcinoma

The state of the science in managing liver diseases such as hepatitis C and

hepatocellular carcinoma are changing rapidly. PVI, PeerView Institute for

Medical Education, can help you keep abreast of the latest treatment strategies,

pathophysiology, and issues while you earn credit.

PVI is offering 3 concise CME/CNE/CPE programs for hepatologists highlighting

advances in management of chronic hepatitis C and hepatocellular carcinoma.

Click on a link below to get started.

Improving Outcomes in Hepatitis C

Improving the Standard of Care for HCV Management: Available and Emerging

Strategies for Optimal Patient Outcomes

Evidence-Based Treatment of Intermediate- to Advanced-Stage Hepatocellular

Carcinoma: Improving Outcomes With Modern Therapies

PeerView Initiatives provide engaging CME/CNE/CPE activities in various formats

and up-to-date clinical information for the practicing clinician.

These activities are supported by educational grants from Bayer HealthCare

Pharmaceuticals, Human Genome Sciences, Inc., Novartis Pharmaceuticals

Corporation, Onyx Pharmaceuticals, Inc., Valeant Pharmaceuticals North America,

and Vertex Pharmaceuticals Incorporated.

Unsubscribe || Privacy Policy || Not a Subscriber?

PVI, PeerView Institute for Medical Education, 315 Bleecker Street, Suite 181,

New York, NY 10014

Recommended Posts